TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Terns Pharmaceuticals
Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

Terns Pharmaceuticals reported promising Phase 1 clinical trial results for TERN-701, an investigational BCR::ABL1 inhibitor for chronic myeloid leukemia (CML), showing 64-75% major molecular response rates and a favorable safety profile across patient subgroups.

Insights
TERN   positive

Reported unprecedented Phase 1 data with high molecular response rates, encouraging safety profile, and potential best-in-disease therapy positioning for TERN-701 in CML treatment